PathoQuest is preparing clinical trials of its next-generation sequencing-based infectious disease diagnostic assay, which it hopes to launch in Europe in early 2015 and later in the US, initially for use in immunocompromised patients.

The Paris-based company, a spinout of the Pasteur Institute and the Ecole Nationale Vétérinaire d'Alfort, ENVA, recently raised €3.8 million ($5 million) in a Series B private equity funding round that it will use to finance the trials as well as to develop its technology further.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

A retrovirus that's been integrated into the human genome appears to have a role in embryonic development, researchers report.

A report from MIT identifies areas of scientific research where declining research support is hindering needed advances.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.

Sponsored by

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.